Insulin secretion and aging: Implications for insulin therapy in the geriatric patient with diabetes mellitus;Insulinsekretion und alter: Implikationen für die insulintherapie des geriatrischen patienten mit diabetes mellitus

Medizinische Klinik

Volumn 98, Issue 5, 2003, Pages 287-291

  Fritsche, Andreas ^a   Stumvoll, Michael ^b   Häring, Hans Ulrich ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Medizinische Universitatsklinik ^*

Author keywords

Endogenous insulin secretion; Geriatry; Insulin therapy

Indexed keywords

INSULIN;

AGE DISTRIBUTION; AGED; AGING; ALGORITHM; CELL FUNCTION; DIABETES MELLITUS; EPIDEMIOLOGICAL DATA; GERIATRIC DISORDER; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN TREATMENT; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PREVALENCE; REVIEW;

AGE FACTORS; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN; ISLETS OF LANGERHANS; SECRETORY RATE; TREATMENT OUTCOME;

EID: 0038287941     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-003-1259-8     Document Type: Review

References (51)

1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782-7.
2. Hauner H, Ferber L von, Köster J. Schätzung der Diabeteshäufigkeit in der Bundesrepublik Deutschland anhand von Krankenkassendaten. Dtsch Med Wochenschr 1992;117:645-50.
3. Hauner H. Verbreitung des Diabetes mellitus in Deutschland. Dtsch Med Wochenschr 1998;123:777-82.
4. Michaelis D, Jutzi E. Epidemiologie des Diabetes mellitus in der Bevölkerung der ehemaligen DDR. Z Klin Med 1991;46:59-64.
5. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer HS, ByrdHolt DD. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: the Third National Health and Nutrition Examination Survey. Diabetes Care 1998;21:518-24.
6. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
7. The DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999;354:617-21.
8. Reaven G. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
9. Porte DJ. β-cells in type II diabetes mellitus. Diabetes 1991;40:166-80.
10. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9.
11. Ferrannini E, Vichi S, Beck Nielsen H, Laakso M, Paolisso G, Smith U. Insulin action and age. European Group for the Study of Insulin Resistance (EGIR). Diabetes 1996;45:947-53.
12. Ferrannini E, Björkman O, Reichard G, Pilo A, Olsson M, Wahren J, DeFronzo R. The disposal of an oral glucose load in healthy subjects: a quantitative study. Diabetes 1985;34:580-8.
13. Pacini G, Valerio A, Beccaro F, Nosadini R, Cobelli C, Crepaldi G. Insulin sensitivity and beta-cell responsivity are not decreased in elderly subjects with normal OGTT. J Am Geriatr Soc 1988;36:317-23.
14. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP, et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 1993;42:1663-72.
15. Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 1981;68:1456-67.
16. Fritsche A, Madaus A, Stefan N, Tschritter O, Maerker E, Teigeler A, Häring H, Stumvoll M. Relationships between age, proinsulin conversion and beta cell function in non-diabetic humans. Diabetes 2002;51:S234-9.
17. Chen M, Bergman RN, Pacini G, Porte D Jr. Pathogenesis of age-related glucose intolerance in man: insulin resistance and decreased beta-cell function. J Clin Endocrinol Metab 1985;60:13-20.
18. Roder ME, Schwartz RS, Prigeon RL, Kahn SE. Reduced pancreatic B cell compensation to the insulin resistance of aging: impact on proinsulin and insulin levels. J Clin Endocrinol Metab 2000;85:2275-80.
19. Rhodes CJ, Alarcon C. What beta-cell defect could lead to hyperproinsulinemia in NIDDM? Some clues from recent advances made in understanding the proinsulin-processing mechanism. Diabetes 1994;43:511-7.
20. Shimizu M, Kawazu S, Tomono S, Ohno T, Utsugi T, Kato N, Ishi C, Ito Y, Murata K. Age-related alteration of pancreatic beta-cell function. Increased proinsulin and proinsulin-to-insulin molar ratio in elderly, but not in obese, subjects without glucose intolerance. Diabetes Care 1996;19:8-11.
21. Meneilly GS, Demuth HU, McIntosh CHS, Pederson RA. Effect of aging and diabetes on glucose dependent insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose. Diabet Med 2000;17:346-50.
22. Ranganath L, Sedgwick I, Morgan L, Wright J, Marks V. The aging entero-insular axis. Diabetologia 1998;41:1309-13.
23. Meneilly GS, Ryan AS, Minaker KL, Elahi D. The effect of age and glycemic level on the response of the beta cell to glucose-dependent insulinotropic polypeptide and peripheral tissue sensitivity to endogenously released insulin. J Clin Endocrinol Metab 1997;83:2925-32.
24. Fritsche A, Stefan N, Hardt E, Häring H, Stumvoll M. Characterisation of beta-cell dysfunction of impaired glucose tolerance. Evidence for impairment of incretin-induced insulin secretion. Diabetologia 2000;43:852-8.
25. Meneilly GS, Veldhuis JD, Elahi D. Disruption of the pulsatile and entropic modes of insulin release during an unvarying glucose stimulus in elderly individuals. J Clin Endocrinol Metab 1999;84:1938-43.
26. Scheen AJ, Sturis J, Polonsky KS, Van Cauter E. Alterations in the ultradian oscillations of insulin secretion and plasma glucose in aging. Diabetologia 1996;39:564-72.
27. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Diabetes 1995;44:863-70.
28. U.K. Prospective Diabetes Study Group. U.K. Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-58.
29. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131:281-303.
30. Bachmann W, Löbe A, Lacher F. Medikamentös bedingte Hypoglykämien bei Typ II Diabetes. Diab Stoffw 1995;4:83-9.
31. Gerich JE. Oral hypoglycemic agents. N Engl J Med 1989;321:1231-45.
32. Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001;24:758-67.
33. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
34. Yki-Järvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, Rajala T, Ryysy L, Salo S, Seppälä P, Tulokas T, Viikari J, Karjalainen J, Taskinen M-R. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992;327:1426-33.
35. Yki-Järvinen H, Ryysy L, Nikkiliä K, Tulokas T, Vanamo R, Heikkilä M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. Ann Intern Med 1999;130:389-96.
36. Wolffenbuttel BH, Sels JP, Rondas-Colbers GJ, Menheere PP, Nieuwenhuijzen Kruseman AC. Comparison of different insulin regimens in elderly patients with NIDDM. Diabetes Care 1996;19:1326-32.
37. Herz M, Sun B, Milicevic Z, Erickson P, Fovenyi J, Grzywa M, Pelikanova T. Comparative efficacy of preprandial or postprandial Humalog Mix75/25 versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus. Clin Ther 2002;24:73-86.
38. Cryer PE. Hypoglycemia is the limiting factor in the management of diabetes. Diabetes Metab Res Rev 1999;15:42-6.
39. Gerich J. Hypoglycaemia and counterregulation in type 2 diabetes. Lancet 2000;356:1946-7.
40. Gerich JE, Mokan M, Veneman T, Korytkowski M, Mitrakou A. Hypoglycemia unawareness. Endocr Rev 1991;12:356-71.
41. Bolli G, Tsalikian E, Haymond M, Cryer P, Gerich J. Defective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus. J Clin Invest 1984;73:1532-41.
42. Levy CJ, Kinsley BT, Bajaj M, Simonson DC. Effect of glycemic control on glucose counterregulation during hypoglycemia in NIDDM. Diabetes Care 1998;21:1330-8.
43. Korzon Burakowska A, Hopkins D, Matyka K, Lomas J, Pernet A, Macdonald I, Amiel S. Effects of glycemic control on protective responses against hypoglycemia in type 2 diabetes. Diabetes Care 1998;21:283-90.
44. Gerich JE. Glucose counterregulation and its impact on diabetes mellitus. Diabetes 1988;37:1608-17.
45. Stumvoll M, Meyer C, Mitrakou A, Nadkarni V, Gerich J. Renal glucose production and utilzation. New aspects in humans. Diabetologia 1997;40:749-57.
46. Arem R. Hypoglycemia associated with renal failure. Endocrinol Metab Clin North Am 1989;18:103-21.
47. Mayka K, Evans M, Lomas J, Cranston I, Macdonald I, Amiel SA. Altered hierarchy of protective responses against severe hypoglycemia in normal aging in healthy men. Diabetes Care 1997;20:135-41.
48. Amiel SA. Hypoglycaemia avoidance - technology and knowledge. Lancet 1998;352:502-3.
49. Yki-Järvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000;23:1130-6.
50. Matsuda A, DeFronzo R. Insulin sensitivity indices obtained from oral glucose tolerance testing. Diabetes Care 1999;22:1462-70.
51. Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Järvinen H, Van Haeften TW, Renn W, Gerich J. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 2000;23:295-301.